Monotherapy versus polytherapy of enoxaparin and hydroxychloroquine for the treatment of COVID-19: A randomized controlled clinical trial
Amira S A Said, Doaa Raghda R S Hussein, Mahmoud Khalil, MD Alzhraa M Fahmy, PhD. Phd of Biotechnology, Ahmed H A Hassanein, Lamiaa N Abdelaty, Mahmoud Doaa, MD Khalil
doi:10.18549/PharmPract.2023.1.2777
Objectives: The current study aims to assess the efficacy and safety of Enoxaparin and hydroxychloroquine (HCQ) used as monothrapy or polytherapy versus standard care alone in Coronavirus 2019 (COVID-19) infected patients. Methods: The current study included two hundred patients with laboratory confirmed COVID-19 infection. Patients admitted to hospital were randomly allocated into four groups: group I: received standard COVID-19 therapy, group II: received Enoxaparin 40mg/day subcutaneously (SC) plus standard therapy, group III: received 400 mg/day HCQ plus standard therapy & group IV: received a combination of 400 mg/day HCQ and Enoxaparin plus standard COVID-19 therapy. The disease progression was evaluated by duration to a negative polymerase chain reaction (PCR), length of hospital or Intensive Care Unit (ICU) stay, and mortality rate. The safety of treatments was evaluated by measuring adverse effects. Results: The length of hospital stay, ICU admission and mortality were significantly decreased in Enoxaparin plus standard COVID-19 therapy group versus other groups. Conclusion: These findings suggest that Enoxaparin was safe, effective, and well tolerated and has a role in decreasing the progression of the disease and its complications while HCQ did not discover any evidence of extra therapeutic benefits.
AUTHOR CONTRIBUTIONS Conceptualization: Amira S.A. Said, Lamiaa N Abdelaty, Alzhraa M. Fahmy, Raghda R.S. Hussein, Ahmed H.A. Hassanein. Data curation: Lamiaa N Abdelaty, Raghda R.S. Hussein., Formal Analysis: Doaa Mahmoud Khalil, Investigation: All authors,Project Administration: All authors, Methodology: Amira S.A. Said, Lamiaa N Abdelaty, Alzhraa M. Fahmy, Raghda R.S. Hussein, Ahmed H.A. Hassanein., Software: Doaa Mahmoud Khalil. Validation: Doaa Mahmoud Khalil., Resources: All Authors. Writing-original draft preparation: All Authors. Writing-review and editing: All Authors. Visualization: All Authors. Project administration: All Authors. Funding acquisition: non, authors have read and agreed to the published version of the manuscript.
FUNDING This research received no external funding.
INSTITUTIONAL REVIEW BOARD STATEMENT The study was conducted in accordance with the Declaration of Helsinki and in accordance with the guidelines of Good Clinical Practice and was approved by the Research Ethics Committee with serial number: REC-H-PhBSU-21013. Also, the study was
INFORMED CONSENT STATEMENT Written informed consent has been obtained from patients.
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
References
Abd-Elsalam, Esmail, Khalaf, Monotherapy versus polytherapy of enoxaparin and hydroxychloroquine for the treatment of COVID-19: A randomized controlled clinical trial, Pharmacy Practice
Albani, Sepe, Fusina, Thromboprophylaxis with Enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study, Clinical Medicine,
doi:10.1016/j.eclinm.2020.100562Billett, Reyes-Gil, Szymanski, Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality, Thromb Haemost,
doi:10.1093/jac/dkaa114Cuker, Tseng, Nieuwlaat, American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis, Blood Adv,
doi:10.1182/bloodadvances.2021005945Drago, Gozzo, Li, Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence, Front Pharmacol,
doi:10.3389/fphar.2020.579886Gilat, Haunschild, Tauro, Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19, Ann Oncol
Johnston, Brown, Stewart, Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial, Clinical Medicine,
doi:10.1016/j.eclinm.2021.100773Lewis, Chaudhuri, Alshamsi, The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials, PLoS One,
doi:10.1371/journal.pone.0244778Maa, Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases, Pharmacol Res Perspect,
doi:10.1002/prp2.293Nadkarni, Bagiella, Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients with COVID-19, J Am Coll Cardiol
Pawlowski, Venkatakrishnan, Kirkup, Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients, Clinical Medicine,
doi:10.1016/j.eclinm.2021.100774Pesavento, Ceccato, Pasquetto, The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience, J Thromb Haemost,
doi:10.1111/jth.15022Rentsch, Beckman, Tomlinson, Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study, BMJ,
doi:10.1136/bmj.n311Sarma, Kaur, Kumar, Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis, J Med Virol,
doi:10.1002/jmv.25898Self, Semler, Leither, Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients with COVID-19: A Randomized Clinical Trial, JAMA -J Am Med Assoc
Shastri, Stewart, Horne, In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of Enoxaparin, PLoS One,
doi:10.1371/journal.pone.0126763Shi, Wang, Wang, Clinical observations of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study, medRxiv,
doi:10.21203/rs.3.rs-154472/v1Spyropoulos, Levy, Ageno, Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19, J Thromb Haemost,
doi:10.1111/jth.14929Tang, Bai, Chen, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost,
doi:10.1111/jth.14817Tang, Cao, Han, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Udwadia, Malu, Rana, Hydroxychloroquine for COVID-19: What is our Current State of Knowledge?, J Assoc Physicians India
Zhang, Ni, Di, Systematic review and meta-analysis of the prevalence of venous thromboembolic events in novel coronavirus disease-2019 patients, J Vasc Surg Venous Lymphat Disord,
doi:10.1016/j.jvsv.2020.11.023Zhou, Dai, Tong, COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemother,
doi:10.1093/jac/dkaa114
